AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03953456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elafibranor 120mg
Description: elafibranor 120mg is a coated tablet for oral administration, once daily
Study NCT03953456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: elafibranor 120mg
Description: elafibranor 120mg is a coated tablet for oral administration, once daily
Study NCT03953456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a coated tablet for oral administration, once daily
Study NCT03953456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a coated tablet for oral administration, once daily
Study NCT02369861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST266
Description: Topical ocular application 4 times per day
Study NCT02369861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Refresh Lubricant Eye Drops
Description: Topical ocular application 4 timer per day
Study NCT01333111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience
Study NCT01333111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode
Study NCT02161406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks
Study NCT02161406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 125 mg of Placebo
Study NCT01969045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enk Fiberoptic Atomizer
Description: Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the felxible bronchoscopy
Study NCT01969045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bronchoscope
Description: Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the felxible bronchoscopy
Study NCT03990142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cutaneous conductance to chlorine by SUDOSCAN
Description: The additional examination, related to this research protocol, corresponds to a record of cutaneous conductance with chlorine. This recording of 2 min 30 is done thanks to SUDOSCAN® within 30 minutes before the dialysis session (before the connection to the dialysis machine) and within 30 minutes after the end of the dialysis with a measurement of the tension blood pressure and heart rate immediately before SUDOSCAN®.
Study NCT00598871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymosin Beta 4 (Tβ4)
Description: There are 2 groups: active drug and placebo. The patients in the active arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times daily (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
Study NCT00598871 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of 0.00% Tβ4(w/w) eyedrops to the affected eye, 2 drops four times a day (QID) (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
Study NCT00619268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 25 mg once per week administered intravenously
Study NCT00619268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg \* 1 time /2 weeks administered intravenously
Study NCT00619268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 10 mg/kg \* 1 time /2 weeks administered intravenously
Study NCT00619268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg administered orally once daily in 6 weeks cycles :4 weeks of treatment followed by 2 weeks off
Study NCT00619268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon alpha-2a
Description: Administered subcutaneously as 9 MU three times per week
Study NCT02043834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes.
Study NCT03058380 — intervention group
Intervention type: OTHER
Intervention: Stated-Preferences Evaluation Instrument
Description: A discrete choice experiment (Stated-Preferences Evaluation Instrument) will be electronically configured using best practice stated-preference methods to quantify preferences for total knee replacement versus unicompartmental knee replacement surgery.
Study NCT04199468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Delta-9-THC
Description: Active Delta-9-THC (0.015 mg/kg) given intravenously (IV)
Study NCT04199468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Delta-9-THC
Description: A placebo dose given intravenously (IV)
Study NCT04199468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Ketamine
Description: Active Ketamine (0.2 mg/kg) given intravenously (IV)
Study NCT04199468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Ketamine
Description: A placebo dose given intravenously (IV)
Study NCT01893853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Exercise intervention trials will consist of a steady-state bout of exercise at \~70% VO2peak and a timed performance test on a cycle ergometer in a heated environment.
Study NCT01893853 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Intervention
Description: Exercise intervention trials will consist of a steady-state bout of exercise at \~70% VO2peak and a timed performance test on a cycle ergometer in a heated environment.
Study NCT01893853 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Intervention
Description: Exercise intervention trials will consist of a steady-state bout of exercise at \~70% VO2peak and a timed performance test on a cycle ergometer in a heated environment.
Study NCT01983462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Study NCT01983462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Study NCT01983462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03374163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intralipid 20%
Description: milky soulation for energey supplement.
Study NCT01636089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicarbonates
Description: sodium bicarbonates 1,4%
Study NCT01636089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: sodium chloride 0,9%
Study NCT03951545 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: First line total knee replacement for gonarthrosis .
Description: Patients requiring 1st line total knee replacement for gonarthrosis with a Hip knee angle (HKA) between 170° and 183°. In the first group (Mechanical) the total knee replacement will be performed with a tibial cut by using extramedullary mechanical sighting and in the second group (Gyroscopic) by using gyroscopic and accelerometric navigation (I-Assist).
Study NCT03951545 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: First line total knee replacement for gonarthrosis .
Description: Patients requiring 1st line total knee replacement for gonarthrosis with a Hip knee angle (HKA) between 170° and 183°. In the first group (Mechanical) the total knee replacement will be performed with a tibial cut by using extramedullary mechanical sighting and in the second group (Gyroscopic) by using gyroscopic and accelerometric navigation (I-Assist).
Study NCT01222663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate
Study NCT01222663 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: standard therapy
Description: Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate
Study NCT01222663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemoperfusion
Description: Extracorporeal hemoperfusion with Toraymyxin PMX-20R and conventional medical therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate.
Study NCT00516490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin acetate
Description: Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
Study NCT00516490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Na Cl %0.9
Description: 0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer
Study NCT05063526 — intervention group
Intervention type: DEVICE
Intervention: ultrasound
Description: ultrasound on diaphragm
Study NCT02963272 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional strategy
Description: Conventional strategy to manage the patients with HF, following the international guidelines.
Study NCT02963272 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ST2-guided strategy
Description: patients wit ST2 over the median are targeted with higher doses of drugs with putative effects on fibrosis and anti HF pathophysiology
Study NCT00523809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg IV Daily Over 30 Minutes for 1 Day
Study NCT00523809 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Stem Cell Transplantation on Day 8.
Study NCT00523809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 IV Daily Over 30 Minutes for 5 Days
Study NCT00523809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m\^2 IV Daily Over 30 Minutes for 2 Days
Study NCT00523809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1.
Study NCT00429650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: increased exercise
Description: Use prescribed number of minutes of exercise 5-6 days per week to maintain weight loss.
Study NCT00429650 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet
Description: Use a prescribed diet to maintain weight loss
Study NCT00429650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Diet
Description: Use a combination of exercise and diet to maintain weight loss.
Study NCT04659317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 5 mg Oral Tablet
Description: Encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed
Study NCT04659317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Encapsulated placebo tablets x24, to take po q6 hours as need for pain
Study NCT00747253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoLITT system
Description: laser treatment with the AutoLITT system
Study NCT00262002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation)
Description: MenACWY-CRM conjugate vaccine formulated without adjuvant was injected IM (intramuscularly) in the anterolateral area of the right thigh.
Study NCT00262002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation)
Description: MenACWY-CRM conjugate vaccine formulated with adjuvant was injected IM in the anterolateral area of the right thigh.
Study NCT00262002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY PS (MenACWY-CRM, polysaccharide vaccine)
Description: MenACWY polysaccharide vaccine was injected in the anterolateral area of the right thigh.
Study NCT01605786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilised PEBS synthetic protein (PfPEBS)
Description: PfPEBS, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131 aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 5μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval.
Study NCT01605786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilised PEBS synthetic protein (PfPEBS)
Description: PfPEBS-LSP, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 30 μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval.
Study NCT01605786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehydragel™ HPA
Description: Aluminium hydroxide adjuvant is being used as the adjuvant for the vaccine and will be used as the comparator in the control group. Vac4all is using Rehydragel™ (Manufacturer Reheis Inc.) which is a highly active protein adsorbent specially compounded for use as a fluid adjuvant. It has low oxide content and is carefully controlled for Al2O3 content and protein binding capacity. It has a lower viscosity than competing adjuvants, which makes it easier to process and handle.~Subjects in the control group will be administered a 0.5 ml injection in a 2-dose schedule at 28 days interval. Each injection will contain approximately 600 µg of Al(OH)3 per injected dose corresponding to 200 µg equivalent of Al3+, similar to the amount being administered in the vaccine group.
Study NCT00684203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Description: Oral tablets; single 20-mg or 40-mg loading dose on first day followed by daily 1-mg or 2.5-mg maintenance dose for 59 days
Study NCT00684203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets; matching placebo for SCH 530348 loading and maintenance doses for 59 days
Study NCT00684203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.
Study NCT00684203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.
Study NCT00684203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: 100 mg two or three times daily for 60 days.
Study NCT00684203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 100 mg two or three times daily for 60 days.
Study NCT00248534 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: given IV days 1,8, 15 and 22
Study NCT00248534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 2hr IV every 28 days post consolidation cycles of Temozolomide (TMZ) (6 cycles TMZ = Consolidation cycles)
Study NCT00248534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Induction Days 1-7 and 15-21 (150mg/m2 PO) Consolidation days 1-5 every 28 days X 6 cycles
Study NCT04077385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval-extinction (R-E) Training
Description: The retrieval-extinction (R-E) training intervention will occur on two consecutive days and consist of (a) retrieval of high calorie food cue-reward associative memories and (b) 60-min extinction training for high calorie foods. During the 5-min of retrieval, participants will observe 30 high calorie food images (e.g., cakes, cookies, muffins, hamburgers, french fries, potato chips, pizza). Images will be presented in E-Prime for 8-s each (2-s delay between images). After the 5-min of retrieval and a 10-min rest period, participants will engage in 60-min of extinction training for high calorie foods consisting of 12, 5-min high calorie food cue sequences: 6 image sequences and 6 real food sequences. The real foods will consist of a small portion of high calorie snack foods such as a single M\&M or potato chip.
Study NCT04077385 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extinction Training
Description: The extinction control group will engage in two consecutive days of intervention consisting of (a) retrieval of memories not associated with high calorie foods and (b) 60-min extinction training for high calorie foods. During the 5-min of retrieval, participants will observe 30 non-food-related neutral images (e.g., office supplies, tools). Images will be presented in E-Prime for 8-s each (2-s delay between images). After the 5-min of retrieval and a 10-min rest period, participants will engage in 60-min of extinction training for high calorie foods consisting of 12, 5-min high calorie food cue sequences: 6 image sequences and 6 real food sequences. The real foods will consist of a small portion of high calorie snack foods such as a single M\&M or potato chip. The 60-min extinction training is the same as the extinction training received by participants in the R-E training intervention.
Study NCT01699698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor markers
Description: Duodenal juice are collected using endoscope and cannula. Tumor markers of collected samples are analyzed. The marker concentration is applied to statistical analysis.
Study NCT02454049 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: beetroot juice
Description: 6mmol nitrate
Study NCT02454049 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sodium nitrate
Description: 6mmol sodium nitrate
Study NCT02454049 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: plain water
Study NCT03020069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGMS Device
Study NCT03020069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Device
Study NCT00238953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Study NCT00709501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disseminating Effective Habits for Long-term Weight Loss
Description: Comparison of weight change among those participants in the weight loss intervention (immediate access to the weight loss website) and those participants in the control group (delayed access to the weight loss website).
Study NCT00709501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Achieve Together website
Description: access to the Achieve Together website immediately (Arm 1) or delayed (Arm 2)
Study NCT00950196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amantadine sulphate
Description: amantadine 5/mg/kg for 2 month- tapered up during 2 weeks at 1 month possibility to increase dosage to 8 mg/kg or reduce it if there are side effects
Study NCT00262002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV (Hepatitis B vaccine)
Description: Hepatitis B vaccine at 2, 4, 6 months of age administered IM in the anterolateral area of the left thigh.
Study NCT01615172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cannulation
Description: The different types of cannulation (aortic versus axillaris) were compared in the postoperative period for neurological deficits in three time periods.(intraoperative, 5.POD, 3 month POD)
Study NCT03099408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Oral
Description: Oral metronidazole 400 mg BID for 7 days at first month.
Study NCT03099408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole and Lactobacillus
Description: Oral metronidazole metronidazole 400 mg BID for 7 days at first month and Lactobacillus vaginal suppositories for 10 days at first month,second month and third month.
Study NCT00600847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desloratadine
Description: single dose for 7 days, oral, 20mg
Study NCT00600847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desloratadine
Description: single dose for 7 days, oral, 5 mg
Study NCT00600847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose for 7 days, oral